Henry Schein Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Henry Schein wird ein jährliches Gewinn- und Umsatzwachstum von 24.7% bzw. 5.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.9% betragen.

Wichtige Informationen

24.7%

Wachstumsrate der Gewinne

20.2%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	18.6%
Wachstumsrate der Einnahmen	5.8%
Zukünftige Eigenkapitalrendite	14.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0L3C - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	14,687	723	733	1,005	10
12/31/2025	14,011	642	655	891	13
12/31/2024	13,346	520	577	791	14
3/30/2024	12,451	346	473	670	N/A
12/30/2023	12,339	416	313	500	N/A
9/30/2023	12,693	445	608	786	N/A
7/1/2023	12,598	458	491	653	N/A
4/1/2023	12,528	478	387	536	N/A
12/31/2022	12,647	538	474	602	N/A
9/24/2022	12,607	638	528	625	N/A
6/25/2022	12,718	650	648	738	N/A
3/26/2022	12,655	646	656	740	N/A
12/25/2021	12,401	631	598	710	N/A
9/25/2021	12,236	626	723	783	N/A
6/26/2021	11,898	606	783	833	N/A
3/27/2021	10,615	438	544	583	N/A
12/26/2020	10,119	403	550	599	N/A
9/26/2020	9,622	591	477	542	N/A
6/27/2020	9,291	585	436	512	N/A
3/28/2020	10,054	713	683	766	N/A
12/28/2019	9,986	701	578	654	N/A
9/28/2019	9,789	488	585	655	N/A
6/29/2019	9,636	444	526	597	N/A
3/30/2019	9,504	438	648	722	N/A
12/29/2018	9,418	431	613	685	N/A
9/29/2018	10,263	304	553	629	N/A
6/30/2018	11,069	352	511	586	N/A
3/31/2018	11,812	377	449	527	N/A
12/30/2017	8,883	293	N/A	546	N/A
9/30/2017	12,264	554	N/A	572	N/A
7/1/2017	11,968	550	N/A	619	N/A
4/1/2017	11,782	534	N/A	668	N/A
12/31/2016	11,572	507	N/A	643	N/A
9/24/2016	11,302	498	N/A	676	N/A
6/25/2016	11,122	492	N/A	605	N/A
3/26/2016	10,879	489	N/A	536	N/A
12/26/2015	10,630	479	N/A	616	N/A
9/26/2015	10,481	482	N/A	563	N/A
6/27/2015	10,419	469	N/A	630	N/A
3/28/2015	10,405	467	N/A	621	N/A
12/27/2014	10,371	466	N/A	593	N/A
9/27/2014	10,196	457	N/A	593	N/A
6/28/2014	9,921	450	N/A	571	N/A
3/29/2014	9,697	442	N/A	647	N/A
12/28/2013	9,561	432	N/A	664	N/A
9/28/2013	9,443	420	N/A	589	N/A
6/29/2013	9,325	409	N/A	515	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0L3CDas prognostizierte Gewinnwachstum (24.7% pro Jahr) liegt über der Sparquote (1.8%).

Ertrag vs. Markt: 0L3CDie Erträge des Unternehmens (24.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (13.1% pro Jahr).

Hohe Wachstumserträge: 0L3CEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 0L3CDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0L3CDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 0L3CDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.9%).

Henry Schein Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year 2022

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.72 (vs US$0.92 in 1Q 2023)

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Insider recently sold US$478k worth of stock

Full year 2023 earnings released: EPS: US$3.19 (vs US$3.95 in FY 2022)

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. announced delayed 10-Q filing

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: US$1.07 (vs US$1.17 in 2Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently sold US$835k worth of stock

Executive VP recently sold US$1.9m worth of stock

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: EPS: US$0.92 (vs US$1.32 in 1Q 2022)

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Independent Director recently sold US$148k worth of stock

Independent Lead Director recently sold US$504k worth of stock

Now 20% undervalued after recent price drop

Independent Director recently sold US$923k worth of stock

Full year 2022 earnings released: EPS: US$3.95 (vs US$4.51 in FY 2021)

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insider recently sold US$1.2m worth of stock

Henry Schein, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Henry Schein, Inc. Announces its Lineup of Products and Solutions At the American Association of Oral and Maxillofacial Surgeons (AAOMS) Annual Conference in New Orleans, La. from September 12 Through September 17

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Midway Dental Supply, Inc.

Henry Schein, Inc. Announces the Passing of Board Member E. Dianne Rekow

Second quarter 2022 earnings released: EPS: US$1.17 (vs US$1.11 in 2Q 2021)

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year 2022

Henry Schein, Inc. Appoints Mark Hillebrandt as Chief Digital Revenue Officer

Henry Schein, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Condor Dental Research Company SA from MCCB Holding Sarl.

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from Russell 1000 Dynamic Index

Henry Schein, Inc. (NasdaqGS:HSIC) entered into a definitive agreement to acquire Condor Dental Research Company SA from MCCB Holding Sarl.

Insider recently sold US$982k worth of stock

Henry Schein, Inc. Appoints Dirk Benson as Chief Commercial Officer of North America Distribution Group

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$1.32 (vs US$1.17 in 1Q 2021)

Henry Schein, Inc. to Report Q1, 2022 Results on May 03, 2022

Henry Schein Inc. Announces Executive Changes, Effective from July 1, 2022

Henry Schein Promotes Jennifer Ferrero to Corporate Secretary, Effective July 1, 2022

Executive VP recently sold US$2.0m worth of stock

Henry Schein to Showcase A Wide Portfolio of Products, Services, and Solutions During the Chicago Midwinter Dental Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Henry Schein, Inc. Provides Earnings Guidance for the Year 2022

Henry Schein, Inc. Announces Lineup of New Products and Solutions At the Greater New York Dental Meeting

Third quarter 2021 earnings released: EPS US$1.16 (vs US$1.00 in 3Q 2020)

Henry Schein, Inc. Announces Not to Provide Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.08 loss in 2Q 2020)

Henry Schein, Inc. (NasdaqGS: HSIC) acquired 70% stake in eAssist Dental Solutions, Inc.

Independent Director has left the company

Independent Director has left the company

Independent Director recently sold US$237k worth of stock

First quarter 2021 earnings released: EPS US$1.17 (vs US$0.91 in 1Q 2020)